Pooled allocation
Reduces waste across all sites. Requires depot visibility that many vendors do not support cleanly across borders.
Global Study Configuration
Multinational trials add language, country-specific supply rules, and depot coordination across borders to RTSM configuration. This page walks through each in the order it surfaces during a study build.
Independent editorial — written for clinical operations teams evaluating RTSM vendors for studies that run beyond a single country.
Country Coverage
"Global coverage" in vendor marketing is not a specific number, and it does not tell you how a country is served. Ask each vendor for a list of countries with a locally supported depot, then a second list of countries served through a regional hub. Those two lists behave very differently during a supply interruption.
A local depot can respond in days. A regional hub response depends on customs, import documentation, and the receiving site's local logistics. The distinction matters most for studies running in countries where import timelines are unpredictable.
Ask For Two Lists
Three Screens To Check First
Site-Facing Interface
The site-facing interface is the part of the RTSM that coordinators actually touch, and it needs to work in the languages your sites use. That includes the randomization screen, the resupply request, and the unblinding workflow.
Ask the vendor which languages are supported out of the box and which are custom. Then ask how the language selection works per site, because a site in one country may have staff working in two or three languages. Vendors who handle this as a per-user setting tend to have better site feedback than vendors who require a per-country configuration.
Allocation Logic
Kit allocation rules that work in one country often do not survive contact with multinational supply. Each approach trades waste against documentation burden, and there is no universally correct answer — the question is whether the system supports the rule your protocol specifies without custom code.
Reduces waste across all sites. Requires depot visibility that many vendors do not support cleanly across borders.
Simplifies regulatory documentation at each site. Increases the total kit count and the discard load at study end.
Matches the randomization scheme directly. Can produce odd depletion curves when enrolment is uneven across countries.
The decision that follows is how much of the rule can be changed after go-live if the enrolment pattern turns out differently than planned.
Depot Coordination
Depot coordination is where most multinational supply problems appear. A shipment that leaves a regional hub on time can still arrive late because of customs or import documentation, and the site only learns about the delay when it tries to allocate the kit.
Systems that provide depot-level visibility let the study team see the shipment in transit and adjust enrolment or resupply before the site runs into a shortage. Systems that do not put the study team in a reactive posture.
Ask specifically how the system tracks in-transit shipments, and how a site can see whether a replacement kit is already on its way.
Emergency Unblinding
Emergency unblinding is straightforward in one country with a single support line. Across many countries it raises questions that have less to do with software than with the procedure the site follows when the sponsor's clinical lead is asleep.
The procedures matter more than the software, though the software has to support them. Test the unblinding workflow from a site's perspective during UAT, ideally with a coordinator in a distant time zone, because that is where the workflow's weaknesses become visible.
Regulatory Variation
Country-specific regulatory documentation for clinical supply can vary in ways that the RTSM configuration does not adapt to automatically. Kit labeling requirements, import documentation, and record-keeping obligations are usually the sponsor's responsibility, not the software's, but the RTSM has to accommodate whatever local rules apply.
Ask the vendor how they handle country-specific labeling in the kit allocation rules, and whether an unusual labeling requirement becomes a custom configuration or sits inside the standard product. The answer affects both your timeline and your amendment cost later in the study.
Where a country applies an unusual rule — a second-language label that must appear on every kit, or an import document that has to accompany each shipment — the RTSM needs to know about it at the kit-allocation level, not only at the label printer.
Add To UAT
Add three scenarios to your UAT script when the study is multinational. Each covers a class of situation that surprises teams after go-live, and each is cheap to run before.
From a site in that country where possible. Coordinators will find the untranslated field before the study team does.
Hold the expected date and see how the system presents the delay. If the site learns only when it tries to allocate, the visibility gap is real.
Using the actual after-hours procedure. Weaknesses in the workflow become visible within the first ten minutes.
The UAT script you bring to study startup is what shows where the vendor's coverage actually holds.
Match The List To Your Sites
The vendor's country coverage matters most where you are running sites in places with slower import timelines, unusual labeling requirements, or a small number of enrolled subjects spread across many locations. A study running only in Western Europe and the US will find most vendors adequate.
A study with sites in multiple regions and unpredictable shipment timelines will find the differences between vendors substantial. Match the vendor's actual coverage to your actual site list, not to a marketing map, and ask for a specific recent example in each country you need.
When Coverage Decides
Ask the vendor for a specific recent example in each country you need, not for a coverage map.
Common Questions
The same four questions come up in almost every study with sites in more than one region. These are the answers we give before a scope discussion.
Editorial Provenance
This page is part of an independent editorial resource on RTSM, IRT, and clinical trial supply decisions. Nothing here is sponsored by a platform vendor, and the comparisons are drawn from the criteria study teams bring to a scope discussion. If a technical detail on this page reads differently than your own vendor documentation, the documentation wins — and we would rather correct the page than argue about it.